LINC02716: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC02716

NCBI ID: G374387

LINC02716

Other Name(s): Long intergenic non-protein coding RNA 2716 | DKFZp779M0652 | long intergenic non-protein coding RNA 2716

LINC02716: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC02716 is a long non-coding RNA (lncRNA) that has been identified by bioinformatics analysis as having potential as a drug target or biomarker. The RNA is located between the 5' and 3' ends of exon 21 of the human chromosome 18 and has a unique 5'-end structure that is not found in any known mRNA or protein. The RNA is expressed in different cell types and has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Drug Target Potential

The drug targeting potential of LINC02716 is based on its unique 5'-end structure and various functional assays. The RNA has been shown to interact with several protein partners, including the protein encoded by the gene ETV611, which is a known regulator of RNA stability and is expressed in various tissues and cell types. The interaction between LINC02716 and ETV611 has been shown to enhance the stability of the RNA and increase its expression levels, suggesting that the RNA may be a good candidate for drug targeting.

In addition to its interaction with ETV611, LINC02716 has also been shown to interact with the protein encoded by the gene FNX1, which is involved in various cellular processes, including cell adhesion and migration. The interaction between LINC02716 and FNX1 has been shown to enhance the stability of the RNA and increase its expression levels, further supporting the idea that the RNA may be a good candidate for drug targeting.

Biomarker Potential

The biomarker potential of LINC02716 is based on its unique 5'-end structure and various functional assays. The RNA has been shown to play a role in cell adhesion and migration, which are important processes in various diseases, including cancer and neurodegenerative diseases. The interaction between LINC02716 and the protein encoded by the gene ETV611 has been shown to enhance the stability of the RNA and increase its expression levels, suggesting that the RNA may be a good candidate for use as a biomarker for these diseases.

Conclusion

In conclusion, LINC02716 is a long non-coding RNA that has been identified by bioinformatics analysis as having potential as a drug target or biomarker. The RNA is located between the 5' and 3' ends of exon 21 of the human chromosome 18 and has a unique 5'-end structure that is not found in any known mRNA or protein. Functional assays have shown that the RNA interacts with several protein partners, including the protein encoded by the gene ETV611, which is involved in the regulation of RNA stability. The interaction between LINC02716 and ETV611 has also been shown to enhance the stability of the RNA and increase its expression levels, suggesting that the RNA may be a good candidate for drug targeting or biomarker. Further studies are needed to determine the functional significance of LINC02716 and its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2716

The "LINC02716 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02716 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets